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Culture and differentiation of human mesenchymal stromal cells and 
human endothelial cells on polymeric scaffolds to improve bone tissue 
engineered substitutes   
 
Abstract 
The purpose of this thesis is the development of a new strategy to improve the bone 
substitutes obtained via tissue engineering. These substitutes are usually achieved by 
culturing in vitro mesenchymal stromal cells (MSCs) and differentiating into osteogenic 
lineage the MSCs grown on three-dimensional porous structures made of biocompatible 
materials, known as scaffolds. One of the problems still to be solved is that these in vitro 
generated substitutes must be vascularized in vivo after implantation. Post-implant 
vascularization is often inadequate and leads to death of the transplanted cells. In this 
thesis several methods were tested to develop in vitro bone substitutes already provided 
with an initial vascularization. Spongy scaffolds made of polyvinyl alcohol (PVA) and 
gelatin (G) were tested with different weight compositions of the two polymers (namely 
PVA/G 100/0, 90/10, 80/20, 70/30, 50/50).  
The experimental work is articulated in the following phases:   
1) Cross-linking of the scaffolds with glutaraldehyde to have the polymeric structures 
stabilized inside an aqueous environment. The morphology of the sponges was observed 
with a scanning electron microscope (SEM) and their stability tested by immersion in water 
for two weeks.   
2) Selection of the type of scaffold for the culture and differentiation of human umbilical 
vein endothelial cells (HUVECs), as an endothelial cell model. The scaffolds were cultured 
for 3 days and the differentiation induced by addition of Matrigel® for 18 hours. Before 
completing these experiments and securing the constructs in formalin, the non-destructive 
viability test AlamarBlue® it was performed to evaluate the metabolic activity of the cells. 
The fixed samples were processed for histological analysis with hematoxylin and eosin. 
The results showed that the scaffolds PVA/G 80/20 were the best about viability and cell 
colonization.   
3) Selection of the type of scaffold for culturing and osteo-differentiation of human MSCs. 
The MSC/scaffold constructs were cultured for 22 days and the differentiation induced by 
addition of ascorbic acid, dexamethasone and β-glycerophosphate for 21 days. Every  
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week the vitality test AlamarBlue® was performed. The samples were fixed in formalin and 
processed for histological analysis with hematoxylin and eosin to assess cell morphology 
and von Kossa to assess the formation of mineral matrix. The results showed that the 
scaffold types PVA/G 80/20 and 70/30 were the best suitable. Therefore, PVA/G 80/20 
was chosen to perform the co-culture with HUVECs.   
4) The co-culture was conducted for 3 days by adding, at the end of osteogenic 
differentiation (day 22), HUVECs to MSC/scaffold constructs, both in the presence and 
absence of Matrigel®. The constructs were fixed in formalin and processed for an 
extensive histological analysis. Immunohistochemistry analyses of endothelial and 
osteogenic markers were performed, in order to localize the two different cell types on the 
scaffold and understand their interaction.   
5) In order to investigate the influence played by bone extracellular matrix alone on the 
differentiation of HUVECs, which in vitro needs Matrigel® to form the tubes, some 
MSC/scaffold constructs at the end of the osteogenic differentiation, were lysed with sterile 
distilled water so as to remove the cellular component and to observe the interaction of the 
HUVECs with the pre-generated bone matrix. An extensive histological analysis was 
carried out. The results of points 4) and 5) finally highlighted the importance of 
osteoblastendothelial cell interaction for endothelial differentiation.   
6) We finally tested this co-culture system under a completely autologous approach. To 
this purpose we used mesodermal progenitor cells (MPCs), which are a subset of highly 
immature stem cells present in the bone marrow and capable of differentiating into both 
MSCs and pre-endothelial cells. The expression of some osteogenic and endothelial 
markers in the construct confirmed results reported in literature and the scaffold PVA/G 
strategy can be used to explore the use of innovative techniques in bone tissue 
engineering.   
 
Keywords: scaffold, MSC, bone substitute, HUVEC, osteogenic, endothelial, 
differentiation, SEM, histochemistry, pre-generated matrix, co-culture. 
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Riassunto 
 
Culture and differentiation of human mesenchymal stromal cells and 
human endothelial cells on polymeric scaffolds to improve bone tissue-
engineered substitutes 
 
Lo scopo di questo lavoro di tesi consiste nella messa a punto di una nuova strategia per 
migliorare I sostituti ossei ottenuti tramite ingegneria tissutale. Tali sostituti generalmente 
si ottengono coltivando in vitro le cellule stromali mesenchimali (MSCs) e differenziandole 
in senso osteogenico su scaffold, ossia strutture porose tridimensionali a base di materiali 
biocompatibili.  
Uno dei problemi ancora da risolvere è che questi sostituti generati in vitro dovranno 
essere vascolarizzati in vivo dopo l’impianto. Questo processo è spesso inadeguato e 
porta alla morte delle cellule trapiantate. In questa tesi sono stati testati alcuni metodi per 
sviluppare in vitro dei sostituti ossei già dotati di una iniziale vascolarizzazione. Come 
scaffold sono state utilizzate spugne di alcool polivinilico (PVA) e gelatina, con varia 
composizione ponderale dei due polimeri (PVA/G 100/0, 90/10, 80/20, 70/30, 50/50).  
Il lavoro di tesi si è articolato nelle seguenti fasi: 
1. Reticolazione degli scaffold con glutaraldeide per stabilizzare le strutture polimeriche 
in ambiente acquoso. La morfologia delle spugne è stata osservata al microscopio 
elettronico a scansione (SEM) e la loro stabilità testata tramite immersione in acqua 
per due settimane. 
2. Selezione delle tipologie di scaffold per la coltura ed il differenziamento delle human 
umbilical vein endothelial cells (HUVEC), come modello di cellule endoteliali. Gli 
scaffold sono stati coltivati per 3 giorni ed il differenziamento indotto tramite aggiunta 
di Matrigel® per 18 ore. Prima di terminare gli esperimenti e fissare i costrutti in 
formalina è stato eseguito il test di vitalità non distruttivo AlamarBlue® che valuta 
l’attività metabolica delle cellule. I campioni fissati sono stati processati per l’analisi 
istologica con Ematossilina ed Eosina. I risultati hanno evidenziato che gli scaffold 
PVA/G 80/20 erano i migliori. 
3. Selezione delle tipologie di scaffold per la coltura ed il differenziamento osteogenico 
delle human MSCs (hMSCs).Gli scaffold sono stati coltivati per 22 giorni ed il 
differenziamento indotto tramite aggiunta di acido ascorbico, dexametasone e β-
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glicerofosfato per 21 giorni. Ogni settimana è stato eseguito il test di vitalità 
AlamarBlue®. I campioni sono stati fissati in formalina e processati per l’analisi 
istologica con Ematossilina ed Eosina e von Kossa, per valutare la formazione di 
matrice minerale. I risultati hanno evidenziato che gli scaffold PVA/G 80/20 e 70/30 
erano i migliori. Sono stati quindi selezionati gli scaffold PVA/G 80/20 per effettuare la 
co-coltura con le HUVEC. 
4. La co-coltura è stata condotta per 3 giorni aggiungendo, al termine del 
differenziamento osteogenico (giorno 22), le HUVEC ai costrutti hMSC/scaffold, sia in 
presenza che in assenza di Matrigel®. I costrutti sono stati fissati in formalina e 
processati per un’analisi istologica approfondita. L’immunoistochimica è in corso per 
valutare i marcatori endoteliali ed osteogenici, in modo da localizzare le due diverse 
tipologie cellulari sugli scaffold e capirne l’interazione. 
5. Nel prosieguo del lavoro abbiamo voluto anche indagare l’influenza che la matrice 
extracellulare ossea da sola può giocare sul differenziamento delle HUVEC, le quali 
nella coltura in vitro necessitano del Matrigel® per formare i tubi. Per questa indagine, 
alcuni costrutti hMSC/scaffold al termine del differenziamento osteogenico, sono stati 
lisati con acqua distillata sterile in modo da rimuovere la componente cellulare e poter 
osservare l’interazione delle HUVEC con la matrice osteogenica pregenerata. Le 
analisi istologiche: citochimici, istochimica, ed immunoistochimica sono stati fatti 
evidenziando così le sue caratteristiche morfologiche, strutturali e biochimici.     
 
Keywords: Scaffold, MSC, Sostituto osseo, HUVEC, osteogenico, endoteliale, 
differenziamento, SEM, Istochimica, matrice pre-generata, co-cultura. 
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ACRONYMS 
 
MSC   Mesenchymal Stromal Cells  
HUVEC  Human Umbilical Vein Endothelial cells 
PVA   Polyvinyl Alcohol 
G   Gelatin 
SEM   Scanning Electronic Microscopy  
ECM   Extracellular Matrix  
EPCs   Endothelial Progenitor Cells. 
TE   Tissue Engineering  
GTA   Glutaraldehyde  
MPC   Mesodermal Progenitor Cells. 
VEGFs  Vein Endothelial Growth Factor      
FGFs   Fibroblast Growth Factors       
TGF-β  Transforming Growth Factor-β 
RUNX-2  Runt related transcription factor-2 
ALP   Alkaline Phosphatase 
FN   Fibronectin  
BMP   Bone Morphogenetic Protein  
DMEM  Dulbecco’s Modified Eagle’s Medium 
EGM-2  Endothelial cells Growth Medium 
BSA   Bovine Serum Albumin 
DAB   Diaminobenzidine Tetrahydrochloride 
EBM-2  Endothelial Cell Basal Medium-2 
FBS   Fetal Bovine Serum 
OPN   Osteopontin 
PECAM  Platelet Endothelial Cell Adhesion Molecule  
VEGF-R2  Vascular Endothelial Growth Factor Receceptor-2 
VEGF   Vascular Endothelial Growth Factor 
OCN   Osteocalcin 
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p-VEGF-R2  anti-Phosphorylated Vascular Endothelial Growth Factor Receptor 2 
PBS   Phosphate Buffered Saline  
MIP   Mercury Intrusion Porosometry  
BMMNCs  Bone Marrow Mononuclear Cells 
H&E   Hematoxylin-Eosin 
IHC   Immunohistochemistry 
MPC   Mesodermal Progenitor Cell 
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Chapter 1 
 
1. INTRODUCTION 
 
1.1. VASCULARIZATION IN BONE REGENERATION 
 
Restoration of bone defects, as a consequence of trauma, tumor excision, chronic 
osteomyelitis, non-union, avascular necrosis and spinal fusions represent a widespread 
clinical problem (Amini et.al, 2012). If the defect is too large, bone regeneration cannot 
occur spontaneously, leading to the necessity of surgical strategies which avail themselves 
of bone substitutes. Materials to replace bone can be biologic or synthetic. The best 
choice, whenever possible, is using bone tissue of the same patient. This is performed by 
taking the bone from a different part of the same person and is referred as autografting. 
However, sometimes the lesion is too big, and auto-transplanting such a great amount of 
bone would generate defects and pain (known as “morbidity”) in a different body setting. 
Limited availability and prolonged surgical times are the drawbacks of autografting 
(Amini,et al, 2012). An alternative is the use of grafts taken from different individuals who 
are dead and decided to donate their tissues. Grafts taken from other human beings are 
called homografts. Finally, sometimes grafts are taken from a different species and they 
are named xenografts. Banked bone has become a useful source of bone substitutes in 
orthopedic surgery. Of course, not autologous grafts (i.e., allografts) must be preliminary 
treated to eliminate the donor’s or animal’s cells, so that they are just composed by bone 
extracellular matrix (ECM)., The use of allografts is advantageous because there is no 
second procedure required to remove and transfer a portion of the patient’s native bone or 
tissue. Surgical time may be minimized, postoperative discomfort reduced and patients 
may be back to normal activities more quickly. However, they place the patients at risk for 
infections and rejection by the immune system, due to the presence of allogeneic proteins. 
Moreover, to promote the vascularization it is necessary to keep the vascular connections 
of vessels to and from a freed segment of bone, (Derby, et.al 2013). Synthetic substitutes 
for bone regeneration can be obtained in the laboratory by growing the patient’s own cells 
on biomaterial-based scaffolds which are designed to further degrade in vivo, and 
transplanting the living bone construct back to the patient. However, the ex vivo procedure 
for obtaining these bone substitutes is very laborious and constrained by strict regulatory 
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issues, so that only a limited number of clinical studies have been reported so far. 
Substitute failures have been highlighted because of their post-implant unsuccessful 
vascularization (Santos et.al, 2010).  The lack of a functional vascular supply after 
implantation put at serious risk the survival of the transplanted cells. Therefore, the 
development of strategies which can promote a microvascularture have become a primary 
goal in bone replacenent. Some studies (Asahara et.al, 2011; Das et.al, 1999) assess that 
the in vivo formation of new blood vessels depends on the ordered interaction of 
endothelial cells with different types of cells including, macrophages, pericytes, endothelial 
progenitor cells (EPCs), and mesenchymal stromal cells (MSCs) (Denber et.al, 1995; 
Wang et.al, 1997). It is has become clear that multiple stem cell types, immunogenic cues, 
and cytokines participate in, and are necessary for initiating angiogenesis and supporting 
osteogenesis. Several strategies have been studied to foster the establishment of a 
functional vascular network in bone substitutes (Santos et al, 2010).They include: (i) 
scaffolds with hierarchical topology, obtained via microfabrication; (ii) scaffolds for 
angiogenic factor release, to recruit endothelial cells in vivo; (iii) microsurgery approach, 
such as flap fabrication and arteriovenous loop, (iv) scaffolds supporting endothelial cell 
attachment and (v) co-cultured systems, in which endothelial cells coexist with bone cells 
at the time of implantation. Because vascularized bone regeneration requires an interplay 
between multiple cell types, recent work has focused on co-culturing different cell types to 
facilitate healing and to most powerfully promote vascularized post-implant bone 
regeneration.   
 
1.2. BONE TISSUE ENGINEERING 
Bone tissue regeneration is considered an important challenge in the field of orthopedic 
and craniofacial surgery. Traumatic injuries and pathological diseases including 
osteoporosis, osteoarthritis, osteogenesis imperfecta, can impair normal bone functions 
and lead to bone fractures non-unions, immobility, severe pain and deformity. As such, the 
request for bone grafts is increasing and represents the second most common tissue 
transplantation procedure after blood, with over 2.2 million bone graft procedures 
conducted worldwide annually in orthopedics and dentistry (K.-U. Lewandrowski et.al, 
2000) (Fernandez-Yague et al, 2015). Novel solutions are required to overcome the 
limitations of current bone grafting approaches through tissue engineering (TE) or 
regenerative medicine which offer promising strategies for treating bone diseases and 
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reconstructing bone defects TE involves the combination of cells, biomaterial scaffolds and 
biochemical and physical stimuli to encourage in vitro tissue formation. The development 
of responsive biomaterials capable of a modulated functionality in response to the dynamic 
physiological and mechanical environments found in vivo remains an important challenge 
in bone tissue engineering to achieve long-term repair and good clinical outcomes 
(Rose,F.R, 2002). 
 
Figure 1 The TE triad. Reproduced by Wójtowicz,2011 
Bone TE has been a field of intense research for about 20 years. However the translation 
to clinical practice is a challenge due to regulatory and ethical issues (Hollister et.al, 2011). 
Nevertheless, bone TE represents the only alternative to traditional bone autografts and 
allografts, and thus further research is needed to face the challenges in this field (Amini 
et.al, 2012). In the following paragraphs, a focus will be given to all the aspects of the TE 
triad which are relevant for this thesis, namely, scaffolds (and polymers), cell sources and 
differentiation stimuli. 
 
1.3.  SCAFFOLDS  
TE scaffolds are biomaterial-based matrices that require several key features: 
 Biocompatibility, to be accepted by the body without causing toxicity, 
carcinogenicity and inflammation 
 Porosity, to host cells and ECM secretion, and to facilitate diffusion phenomena 
 Pore interconnectivity, to allow cell migration, scaffold colonization and 
nutrient/waste trafficking 
 Biodegradation, to be replaced by new tissue 
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A good stratagem for regenerative bone therapies is to use biomaterial scaffold that can 
modulate the process of healing while providing mechanical support. Successively, 
following initial cellular colonization, the material should degrade by cellular and enzymatic 
activity in parallel with the production of new bone matrix. Ideally, after total degradation of 
the scaffold, the tissue will recover its function without the need of clinical intervention to 
remove the implant. Nevertheless, this is frequently not enough to repair the complete 
functionality of the tissue.(Fernandez-Yague et.al,2015). The design and development of 
biomaterial scaffolds that will replace the form and function of native tissue while 
promoting regeneration without necrosis or scar formation is a challenging area of 
research. Different biomaterial scaffolds have been explored for bone regeneration, with 
the aim of identifying the most appropriate physical, chemical and biological properties to 
encourage in vitro bone production (Williams et.al,2005). Two distinct biomaterial based 
approaches have emerged that have demonstrated potential to support stem cell based 
bone regeneration; the use of polymer-based scaffolds (natural and synthetic polymers), 
as they are bioresorbable, and the use of ceramic scaffolds that mimic the mechanical 
environment of mature bone, or a combinational approach of these. Bone scaffolds for 
tissue regeneration require an optimal trade-off between biological and mechanical criteria. 
Optimal designs may be obtained using topology optimization and prototypes produced via 
additive manufacturing techniques(Coelho,et.al, 2015). The most common strategy 
employed to engineer bone is to use a scaffold combined with osteoblast cells, or cells that 
can mature/differentiate into osteoblasts and growth factors that promote cell attachment, 
differentiation, and mineralized bone formation. However, the requirements for designing 
and production of an ideal scaffold for bone regeneration are very complex and not yet 
fully understood. It is generally agreed that the scaffold must be a biocompatible, porous 
(more than 90% porosity and pore sizes 100-350 μm are desirable for bone regeneration), 
interconnected, and permeable structure in order to permit the ingress of cells and 
nutrients. Clearly, structures designed with fibers can meet these criteria, however also 
sponges can be suitable. A better understanding of the basic events during the bone 
healing process have provided new strategies for the development of smart scaffolds that 
are able to biochemically mimic the natural ECM environment of bone tissue. As well as 
providing tailored physicomechanical cues for induction of osteospecific function and 
maintenance of phenotype, these smart biomaterials can deliver key cellular components 
or signaling moieties through regulated release of single or multiple biofactors to promote 
regeneration. 
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1.3.1 POLYVINYL ALCOHOL (PVA). 
Polyvinyl alcohol (PVA) is a water-soluble synthetic polymer, with the formula [CH2-
CH(OH)]n, that is prepared by vinyl acetate polimerization. PVA has excellent film forming, 
emulsifying and adhesive properties. Since PVA is highly hydrophilic, its mechanical 
properties depend on the water content. PVA has a melting point of 230°C and 180-190°C, 
for the fully hydrolyzed and partially hydrolyzed grades, respectively. It is used industrially 
in papermaking, textiles, and in some biomedical applications. PVA is a nonhazardous 
material, has no negative effect on animals, and does not cause any injuries to the skin 
upon contact. PVA hydrogels can be obtained via freeze-thawing or chemical cross-linking 
(Peppas and Hansen, 1982) and have shown relevance in several TE applications, 
especially of soft tissues (Woerly et al., 1996; Hubbell, 1998), like arterial models (Chu and 
Rutt, 1997), heart valves (Jiang et al., 2004), corneal implants (Vijayasekaran et al., 1998), 
and cartilage (Stammen et al., 2001). Moreover, PVA nano-ﬁbrous membranes with 
different compositions could have different clinical applications, especially the controlled 
release of drugs and bone tissue engineering (Preetti,2015). Unlike most famous aliphatic 
polyesters (e.g., polylactic acid, polycaprolactone) PVA is water-soluble, so it can be easily 
blended with most biological molecules, including growth factors and proteins. 
 
1.3.2 GELATIN  
Among proteins, gelatin (G) is widely use in TE. G derives from the hydrolysis of collagen, 
which is the key ECM component in the skeletal system, including skin, cartilage and 
bone. As such, G exerts a pivotal role in cell adhesion and is routinely used to pre-coat 
synthetic scaffolds upon cell seeding. Since G is soluble at 37°C, it is used blended with 
synthetic polymers upon fabrication. This latter approach leads to materials mixtures which 
are referred to bioartificial materials. In addition to the gel-forming, G shows an excellent 
versatility in amino acid composition, including both positively charged (arginine, lysine, 
and histidine) and negatively charged (glutamic acid and aspartic acid) amino acids.  
Biodegradability, biocompatibility, non-immunogenicity, and relatively low cost render G an 
appealing biomacromolecule in TE scaffolding. Chemical cross-linking is the most widely 
used technique to improve the thermal, mechanical and water stability. One strategy uses 
glutaraldehyde (GTA) for its excellent efficiency on the stabilization of collagenous 
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materials and reduced toxicity at low concentrations (Farris et al, 2010). The cross-linking 
of gelatin mediated by GTA is believed to occur via the unprotonated ε-amino groups of 
lysine and hydroxylysine and the amino groups of the N-terminal amino acid. G ﬁbers 
produced through electrospinning found many biomedical applications, including wound or 
burn dressings, surgical treatments, and tissue engineering of bone, skin, and cartilage. 
This is mainly derived from the fact that G is a natural polymer that has well-known wound 
healing abilities and a biological aptitude for stimulating cell proliferation. Furthermore, G 
ﬁbers can be easily extended into three-dimensional structures of woven, knitted, and 
nonwoven structures.   
 
1.4. BONE MARROW STEM CELLS 
1.4.1 Mesenchymal Stromal cells  
Mesenchymal stromal cells (MSCs) are multipotent cells that can be isolated from several 
human tissues and expanded ex vivo for clinical use. Their adherent properties, immune 
phenotype characteristics and differentiation potential have MSC cells a population of cells 
able to improve in differents approach in regeneration tissue. The bone marrow contains 
many different types of cells. Among them are blood stem cells (also called hematopoietic 
stem cells; HSCs) and a variety of different types of cells belonging to a group called 
‘mesenchymal’ cells. Only about 0.001-0.01% of the cells in the bone marrow are 
mesenchymal stromal cells. These cells were first isolated and characterized by 
Friedenstein and his colleagues in early 1974. MSCs, are a subset of non-hematopoietic 
adult stem cells that originate from the mesoderm. They possess self-renewal ability and 
multilineage differentiation into not only mesoderm lineages, such as chondrocytes, 
osteocytes and adipocytes, but also ectodermic cells and endodermic cells 
(EuroStemCells.org). MSCs exist in almost all tissues. They can be easily isolated from 
the bone marrow, adipose tissue, the umbilical cord, fetal liver, muscle, and lung and can 
be successfully expanded in vitro. In the lasts 10 years is rising use the MSCs in clinical 
trials and regenerative medicine, in countries China, Europe and United States. (Stlotz 
et.al,2015) 
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Figure 2 MSCs. Reproduced by EuroStemCells.org 
 
1.4.2 Mesodermal progenitor cells (MPC). 
 
Mesodermal progenitor cells (MPCs) are a subset of stem cells present in the bone 
marrow that have recently been isolated when culturing human bone marrow derived cells 
in the presence of autologous serum (hAS) (Petrini et.al 2008). These adherent cells have 
been identified among MSCs when cultured in a medium supplemented with hAS. MPCs 
are more immature than MSCs and differ from MSCs in terms of their morphology (large, 
round cells) and of their quiescent status (Ki67-negative). MPCs are able to differentiate 
into MSCs when cultured in a medium supplemented with FBS or human cord serum, and 
have been proven to be capable of generating colon forming unit-fibroblasts (CFU-F) 
which can further differentiate into mesodermal lineages (adipocytes, chondrocytes, and 
osteoblasts), as described for MSCs (Bruder et.al,1997). MPCs do not directly differentiate 
into the mesodermal lineage (osteogenic, chondrogenic, adipogenic) even in the presence 
of appropriate stimuli. Moreover, these cells may differentiate into endothelial cells when 
cultured in an appropriate vascular endothelial growth factors (VEGFs)-containing medium 
similar to those used in the differentiation of embryonic cells.  
MPCs are positive for CD105 (but negative for CD90), express high levels of aldehyde 
dehydrogenase (ALDH) activity, and are positive for several markers, such as SSEA4, 
Oct-4, and NANOG, which are also expressed in embryonic cells. They show strong 
plastic adherence and trypsin resistance.  
 
 
19 
 
1.5. ENDOTHELIAL CELLS  
 
The Human Umbilical Vein Endothelial Cells (HUVECs) are cells derived from the 
endothelium of veins from the umbilical cord, these cells offer a classic model system to 
study the different  aspects associated to endothelial function and disease, such as 
normal, abnormal and tumor-associated angiogenesis, oxidative stress, hypoxia and 
inflammation related pathways in endothelia under normal and pathological conditions, 
cardiovascular-related complications associated with various diseases, mode of action and 
cardiovascular protection effects of various compounds, and so on (Park,et al 2006) In 
previously works, the HUVECs have been selected and tested to demonstrate stimulation-
dependent angiogenesis and key endothelial cell signaling pathways (e.g., 
phosphorylation of VEGFR, Akt, MAPK, and expression of Tie2, eNOS, Axl and Etk/Bmx). 
The obtained evidences indicated that HUVECs are an important in vitro model useful in 
molecular medicine including pathophysiology of atherosclerosis and plaque formation, 
and mechanisms for the control of angiogenesis or neovascularization in response to 
hypoxia and inflammation in tumors, ischemic tissue, and in embryogenesis (De Paola and 
Burn 2005)(Park et.al, 2006). 
It is know that the culture of HUVECs on Matrigel®, an extract of endothelial basement 
membrane, results in the formation of honeycomb-like structures that simulate tube 
formation by endothelial cells in vivo. Other in vitro assays which are based on Matrigel® 
involve cell migration, proliferation, cell invasion, protease activity and tubule formation. 
The in vitro formation of capillary-like tubes by endothelial cells on a basement membrane 
matrix is a powerful in vitro method to screen for various factors such as VEGFs, fibroblast 
growth factors (FGFs), angiopoietins, transforming growth factor-β (TGF-β), platelet-
derived growth factors (PDGFs), tumor necrosis factor-α (TNF-α), epidermal growth factor 
(EGF), interleukin-8 (IL-8), and angiogenin, which are secreted by inflammatory cells, 
pericytes, keratinocytes, or tumor cells that promote or inhibit angiogenesis. The use of 
Matrigel® was primarily described in 1988 (Kubota et.al 1988), numerous uses of the 
assay have been developed, such as determining angiogenic or antiangiogenic factors, 
genes regulating and pathway angiogenesis regulation (Arnaoutova et.al, 2010). 
Cells initially attach to the matrix, then migrate toward each other, align and form tubes, 
but for the formation of these tubes the protein synthesis, as well as collagen synthesis 
and proteases are essential. 
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While VEGF is also responsible for increasing vascular permeability, Ang1 through its 
receptor Tie2 inhibits vascular leakage, but also is chemotactic to endothelial cells and 
induces endothelial cell sprouting and secretion of proteases plasmin and MMP-2, 
stimulating angiogenesis, Ang1 is constitutively expressed in the adult (Raundhaug 
et.al,2005) 
 
1.6. OSTEOGENIC DIFFERENTIATION 
 
MSCs have been shown to possess the capability to differentiate into a variety of skeletal 
cell types, including adipocytes, osteoblasts, chondrocytes, and myoblasts upon a proper 
stimulation. Although it is currently believed that the therapeutic benefits of MSCs are due 
to more complicated mechanisms, they have been indicated to be able to differentiate into 
osteoblasts, cardiomyocytes and other tissue-specific cells also after their in vivo systemic 
infusion in the treatment of osteogenesis imperfecta and myocardial infarction in both 
animals and humans (Wei et.al,2013). Possibly, these cells can target the injured tissue 
and receive proper stimulation from the native microenvironment. MSCs can be combined 
together with various natural and synthetic biomaterial scaffolds. Either undifferentiated or 
differentiated MSCs can be loaded onto scaffolds before their implantation into damaged 
tissue sites (Wei et,al,2013). In vitro, chemical factors as well as mechanical stimuli and 
architectural cues of the scaffold have been discovered to be able to address the fate of 
MSCs, thus demonstrating that MSCs are highly responsive to the surrounding 
environment. Such technologies have been successfully applied in cartilage repair and 
long bone repair, with the generation of well-integrated and functional hard tissues 
(Amado,2005). The advantage of a tissue-engineered MSC delivery system relies on the 
ease of controlling and manipulating the implanted cells and tissues, with reduced side 
effects impacting other organs and tissues. Current improvements in delivery vehicles and 
compatibility between the scaffolds and MSCs will help to develop a mature technology for 
clinical applications. The osteogenic potential of MSCs is well known and subsequently 
these cells have a great application value for promoting bone regeneration and relate 
process. Molecularly, the osteogenic differentiation is transcriptionally regulated by runt 
related transcription factor-2 (RUNX2) (Rocca, 2013;Krause et al, 2001)  and nuclear 
localization of β­catenin through canonical WNT signaling (Bruschini et al, 1991)(Bruschini 
et al, 1992). Together this leads to downstream activation of the canonical bone genes – 
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osterix, osteopontin, and osteocalcin [19] and [20] – and suppression of chondrogenesis 
(Janeke,1975). The expression of Runx2 is noticed first in osteocondroprogenitors at early 
bone development. The levels of Runx2 increased in later stages of osteoblastic 
differentiation, with a maximum of observed in osteoblast mature expression. Runx2 acts 
in stages of induction, proliferation, and maturation of osteoblasts also controls the bone 
differentiation by binding to regulatory elements of the considered marker gene promoters 
for different stages of differentiation osteoblastic (Rocca,2011). Furthermore, is know that 
Collagen type I molecule present during the osteogenic differentiation is the primary 
product of osteoblasts in the course of the formation of the bone matrix, which constitutes 
approximately 90% of the total bone mature organic ECM. The protein is also evidently 
expressed at the preosteoblast stage, and moreover, it has been documented that the 
increase of collagen type I expression occurs before the increase of any other matrix 
molecule and before the alkaline phosphatase (ALP) (Stein,et al 1990) and (Clarke,2008) 
Osteopontin is a protein involved in cell aggregation process and is specifically localized in 
lamellar bone extracellular matrix during endochondral ossification and intramembranous. 
Among osteoblastic markers, osteocalcin is currently considered the most specific and the 
last to be expressed. Fibronectin (FN) is an adhesion molecule localized predominantly in 
the pericellular matrix and characterized by a portion capable of binding to collagen. FN is 
a multifunctional, extracellular matrix glycoprotein composed of two nearly identical 
disulfide bound polypeptides of molecular weight 220 kDa is involved in the processes of 
migration, adherence to the matrix and organization of bone cells. 
 
In vitro osteogenesis of MSCs is typically initiated in the plastic adherent cell population by 
dispensation of ascorbic acid, β­glycerol phosphate, and dexamethasone or bone 
morphogenetic protein (BMP).  
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Figure 3 Osteoblast differentiation 
 
Tissue engineering approaches comprise the combination of cells, biomaterial scaffolds 
and specialized culture conditions incorporating biochemical and physical stimuli to 
encourage in vitro bone formation for the adequate functionality. The advance of 
responsive biomaterials capable of modulated functionality in response to the dynamic 
physiological and mechanical environments found in vivo remains an important challenge 
in bone tissue engineering to achieve long-term repair and good clinical outcomes 
(Fernandez-Yague,2015).  
 
1.7. CO-CULTURE AND PRE-VASCULARIZED BONE SUBSTITUTES 
Bone is a complex tissue which comprises many cell populations. Therefore, it is expected 
that the co-culture of heterogeneous cell types will mimic more closely the in vivo 
environment [Fuchs et al, 2009]]. One of the fundamental heterotypic cross-talks in bone 
cells is that between osteoblasts and endothelial cells. A number of studies assessed this 
strong relationship and designed strategies based on the contemporaneous culture of 
these two cell types to regenerate prevascularized bone sobstitutes (kaigler et al. 2003; 
Fuchs et al. 2009). Co-cultures of human osteoblasts and HUVECs were performed on 
scaffolds made of different polymers, like polyurethane, starch/polycaprolactone and 
collagen gel (Santos et al. 2008). Human osteoblasts were also co-cultured with 
endothelial progenitor cells on polycaprolactone/hydroxyapatite scaffolds leading to the 
formation of capillary networks and osteoids (Vandervord et al. 2005). Finally, MSCs and 
endothelial cells were cultured together using a scaffold-free approach and on poly(lactic-
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co-glycolic acid) scaffolds. All these studies reported that the co-culture strategy promotes 
micro-vasculature formation, which was stable in vitro up to 40 days, thus highlighting the 
importance of osteoblast-endothelium cross-talk in recreating the bone microenvironment. 
Among the ECM molecules, collagen type I was highly expressed in these co-cultures. 
Collagen type IV, the main component of the basement membrane was detected in the 
perivascular regions. In addition, endothelial cells can enhance the expression of ALP 
activity, a marker of osteogenesis. The process leading to capillary formation seemed to 
be hindered by adding the osteogenic culture media to the endothelial cells, and by a 
separation of the two cell population using a membrane, while it was amplified by direct 
cell-cell contacts (Finkenzeller et al. 2006). This interesting finding was explained by the 
formation of gap-junctions between osteoblasts and endothelial cells, that were studied 
through the expression of connexin 43 (Cx43) (Villars et al. 2002). Although the co-culture 
method seems a promising strategy, further studies should determine whether these 
microcapillary-like structures pre-formed in vitro within the biomaterial scaffolds will be able 
to integrate with the host microvasculature. 
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Chapter 2 
 
2. MATERIALS AND METHODS  
 
2.1. MATERIALS AND WORK PLAN  
List of reagents and materials  
Alamar Blue, Gibco by Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA, 
product code: DAL1025. 
Alcian blue kit, Bio-Optica, Milan, Italy, product code: 04-161802. 
Aluminium sulphate hydrate, Sigma-Aldrich, St. Louis, MO, USA, product code: 227617. 
Ascorbic acid, Millipore, Temecula, CA, USA, product code: 2004011. 
Biotinylated goat anti-mouse secondary antibody, Vektor Lab, Burlingame, CA, USA, 
product code: BA-9200. 
Biotinylated goat anti-rabbit secondary antibody, Vektor Lab, Burlingame, CA, USA, 
product code: BA-1000. 
Bovine Serum Albumin (BSA), Sigma-Aldrich, St. Louis, MO, USA, product code: A2153. 
Dexamethasone, Millipore,Temecula,CA,USA, product code: 90357.  
Diaminobenzidine tetrahydrochloride (DAB),  Amresco, Solon, OH, USA, product code: 
E733. 
Differentiation Basal Medium-Osteogenic, Lonza, Basel, Switzerland,  product code: PT-
3924. 
Di-sodium hydrogen phosphate anhydrous, Carlo Erba, Milano, Italy, product code: 
480141. 
DPX mountant, Sigma-Aldrich, St. Louis, MO, USA, product code: 06522. 
Dulbecco’s modified Eagle’s medium (DMEM), Gibco by Life Technologies, Thermo Fisher 
Scientific, Waltham, MA, USA, product code: 11880-028. 
Endocult StemCell Techologies, Vancouver, Canada, product code: 05900 
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Endothelial Cell Basal Medium-2 (EBM-2) Clonetics by Lonza, Basel, Switzerland,  product 
code: CC-3156. 
Endothelial cells Growth Medium (EGM-2) medium, Clonetics by Lonza, Basel,  
Switzerland,  product code: CC-3156. 
Eosin B, Sigma-Aldrich, St. Louis, MO, USA, product code: 45260. 
Ethanol 99.8%, Sigma-Aldrich, St. Louis, MO, USA, product code: 02860.  
Fetal Bovine Serum (FBS), Life Technologies, Thermo Fisher Scientific, Waltham, MA, 
USA, product code: 10500064. 
Ficoll Paque Plus, GE healthcare, Hatfield, UK, product code: 17-14440-02. 
Fluconazole,  Fresenius Kabi, Verona, Italy, product code: ATC J02AC01. 
Fluromount, Sigma-Aldrich, St. Louis, MO, USA, product code: F4680. 
Gelatin Bovine Skin  B, Sigma-Aldrich, St. Louis, MO, USA, product code: G9391. 
Glutaraldehyde (25%), Sigma-Aldrich, St. Louis, MO, USA, product code: 49630. 
Glycine, Sigma-Aldrich, St. Louis, MO, USA, product code: 410225. 
Goat Serum, Vektor Lab, Burlingame, CA, USA, product code: S-1000. 
Histoplast LP, Thermo Fisher Scientific, Waltham, MA, USA, product code: 8332.  
Human Fibronectin, BD Bioscience, Erembodegem, Belgium, product code: 356008 
Human umbilical vein endothelial cells (HUVEC), Promocell, Heidelberg, Germany, 
product code: C-12200. 
L-glutamine, Sigma-Aldrich, St. Louis, MO, USA, product code: G7513. 
Matrigel, BD Bioscience, Erembodegem, Belgium, product code: 354234 
Mayer’s Hematoxylin solution, Sigma-Aldrich, St. Louis, MO, USA, product code: MHS32. 
Methanol,  Sigma-Aldrich, St. Louis, MO, USA, product code: 32213.  
Mouse monoclonal antibody Alkaline Phosphatase (ALP), Santa Cruz Biotechnology, 
Santa Cruz, CA, USA, product code: sc-166261.  
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Mouse monoclonal primary antibody anti-Osteopontin (OPN), Santa Cruz Biotechnology, 
Santa Cruz, CA, USA, product code: sc-21742.  
Mouse monoclonal primary antibody anti-Platelet/endothelial cell adhesion molecule-1 
(PECAM), Santa Cruz Biotechnology, Santa Cruz, CA, USA, product code: sc-81158.  
Mouse monoclonal primary antibody anti-Vascular endothelial growth factor receptor 2 
(VEGF-R2), Santa Cruz Biotechnology, Santa Cruz, CA, USA, product code: sc-6251.  
Mouse monoclonal primary antibody anti-Vascular endothelial growth factor (VEGF), 
Santa Cruz Biotechnology, Santa Cruz, CA, USA, product code:  sc-7269.  
NaCl solution (0,9%), Fresenius Kabi, Verona, Italy, product code: B100407. 
NH OsteoDiff Medium,Miltenyi Biotec, Bergisch.Gladbach, Germany,product code:130-
091-677 
NH CondroDiff Medium Miltenyi Biotec, Bergisch.Gladbach, Germany,product code130-
091-679 
NH AdipoDiff Miltenyi Biotec, Medium Bergisch.Gladbach, Germany,product code: 130-
091-677 
Neutral Buffered Formalin (10% aqueous solution containing formaldehyde 4% w/v), Bio-
Optica, Milan, Italy, product code: 05-k01009. 
Nuclear Fast Red, Sigma-Aldrich, St. Louis, MO, USA, product code: 60700. 
Osmium tetroxide (4% w/v solution),  Electron Microscope Sciences, Hatfield, PA, USA, 
product code: 19170 
Osteogenic differentiation medium, Lonza, Basel, Switzerland product code: PT-4120. 
Penicillin/streptomycin, Sigma-Aldrich, St. Louis, MO, USA, product code: P0781. 
Periodic acid, Sigma-Aldrich, St. Louis, MO, USA, product code: 77310. 
Phosphate-buffered saline (PBS) 1X, Gibco by Life Technologies, Thermo Fisher 
Scientific, Waltham, MA, USA, product code: 14190169. 
Poly(vinyl alcohol) (PVA) 99+% hydrolyzed, Mw 89000-98000, Sigma-Aldrich, St. Louis, 
MO, USA, product code: 341584. 
Pyrogallol , Sigma-Aldrich, St. Louis, MO, USA, product code: 16040. 
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Rabbit polyclonal primary antibody anti-Collagen I, abCam, Cambridge, MA, USA, product 
code: ab34710. 
Rabbit polyclonal primary antibody anti-Osteocalcin (OCN), Santa Cruz Biotechnology, 
Santa Cruz, CA, USA, product code: sc-30044.  
Rabbit polyclonal primary antibody anti-Phosphorylated vascular endothelial growth factor 
receptor 2 (p-VEGF-R2), Santa Cruz Biotechnology, Santa Cruz, CA, USA, product code: 
sc-101820.  
Rabbit polyclonal primary antibody anti-Transforming Growth Factor beta-1 (TGFβ-1) 
Santa Cruz Biotechnology, Santa Cruz, CA, USA, product code: sc-146.  
Schiff’s reagent, Titolchimica, Rovigo, Italy, product code: TC71800PP. 
Silver nitrate, Sigma-Aldrich, St. Louis, MO, USA, product code: 209139. 
Sodium chloride, Carlo Erba, Milano, Italy, product code: 479687. 
Sodium dihydrogen phosphate, Carlo Erba, Milano, Italy, product code: 480087. 
Sodium dodecil sulphate, Sigma-Aldrich, St. Louis, MO, USA, product code: 71725 
Sodium thiosulphate pentahydrate, Sigma-Aldrich, St. Louis, MO, USA, product 
code:S8503. 
Triton x100, Sigma-Aldrich, St. Louis, MO, USA, product code: X100. 
Vascular endothelial growth factor (VEGF), Miltenyi Biotec, Cologne, Germany, product 
code: 130-094-029  
Vectastain Elite ABC Kit Standard, Vektor Lab, Burlingame, CA, USA, product code: 
PK6100. 
Xylenes, Sigma-Aldrich, St. Louis, MO, USA, product code: 534056.  
β-glycerol 2-Phosphate.Millipore, Darmstadt, Germany, product code: 2004010. 
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Work plan 
The experimental campaign is organized according to the following steps, as shown in 
Figure 2.1: 
1. PVA/G scaffold preparation with different compositions: 100/0, 90/10, 80/20, 70/30 
and 50/50, and characterization 
2. Selection of the best suitable scaffold for HUVECs 
3. Selection of the best suitable scaffold for osteogenic differentiation of MSCs 
4. Co-culture of osteoinduced MSCs and HUVECs on the selected scaffold, and 
identification of controls to analyze the outcomes. In particular: 
i) verification of the necessity of Matrigel® in presence of bone ECM (+ Matrigel 
and – Matrigel) 
ii) verification of necessity of osteoblast-endothelial cell interaction for 
microcapillary formation (+ live differentiated MSCs, - live differentiated MSCs: 
this was done by lysis of the osteoinduced constructs before HUVEC seeding 
and will be named “pre-generated ECM”) 
5. Optimization of the outcomes 
Generation of a fully autologous pre-vascularized bone substitute using MPC-derived pre-
endothelial cells and MPC-derived osteoinduced MSCs. 
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Figure 2.4.Experimental work plan of the thesis 
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2.1.1 OBJECTIVES  
 
1) Development of a new strategy to improve the bone substitutes obtained via tissue 
engineering. 
 
2) MSC/HUVEC culture and differentiation on three-dimensional porous structures 
made of biocompatible materials, known as scaffolds. 
 
3) Perform co-culture system under a completely autologous approach using MPC 
differentiating into both MSC and pre-endothelial cells. 
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2.2  METHODS 
 
2.2.1. Scaffold fabrication  
Bioartificial PVA/G sponges were fabricated via emulsion and freeze-drying followed by 
chemical crosslinking. Specifically, an 11.72% aqueous solution of PVA prepared via 
autoclaving 1 h at 121°C was cooled down to 50°C under stirring at 1000 rpm inside a 
thermostatic bath. G was added to the PVA solution to reach the following weight ratios 
between the synthetic polymer and the biomolecule:  PVA/G 100/0, 90/10, 80/20, 70/30 
and 50/50 w/w. For each composition, a soft paste was thus obtained heating up the 
mixture to 71°C for 10 min. Thereafter, the bath temperature was cooled down again to 
50°C, and 0.36% (w/v) of SDS was added to the mixture whereas stirring at 1000 rpm was 
continued for 10 min, leading to the obtainment of a voluminous dense foam that was 
spread on petri dishes with a large spatula, frozen at  -80°C and lyophilized. The dried 
foams were stabilized by crosslinking via GTA vapors for 72 h at 37°C in a sealed cabinet 
and then flushed under the chemical hood for 48 h, thus obtaining biostable sponge-like 
materials. For in vitro experiments, the scaffolds were cut into cylinders of 5 mm diameter 
and 2 mm thickness using a puncher. and the samples were sterilized in absolute ethanol 
overnight, soaked in 2% Glycine for one hour to block the un-bound sites of GTA, rinsed 
three times with sterile 1× phosphate-buffered saline (PBS) of 15 minutes each, and finally 
dried under laminar flow cabinet inside Well-plates. All scaffolds will seeded with MSC and 
HUVECs cells to select the best performing scaffold. 
 
 
 
 
 
 
 
 
 
Figure 5.2. Scaffold fabrication 
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2.2.2. Morphological analysis of the scaffolds. 
Scanning electron microscopy (SEM) was used to analyze scaffold morphology, as well as 
cell attachment, morphology and spreading on to the scaffolds. The biological samples 
were dehydrated with two washings in 80% ethanol for 10 minutes, followed by one 
washing in 90% ethanol for 15 minutes, one in 95% ethanol l and finally three washing, 
each one of 20 minutes, in absolute ethanol. The biological samples were dried in oven at 
37°C for two hours prior to sputter coating, Differently, plain scaffolds were obtained after 
freeze-drying, so they could be sputter coated directly. All the dried samples were thus 
mounted on aluminum stubs, sputter-coated with gold (Sputter coater Emitech K550, 
Quorum Technologies Ltd, United Kingdom.), and observed via SEM. (JSM-5200, JEOL 
Ltd, Tokyo, Japan; Zeiss EVO MA 10, Carl Zeiss Industrielle Messtechnik GmbH, 
Oberkochen, Germany). 
 
2.2.3. Pore size analysis of the scaffolds 
Pore size and distribution of the lyophilized sponges were investigated via mercury 
intrusion porosometry (MIP). An Hg intrusion porosimeter (Pascal 140; Carlo Erba, 
Pomezia, Italy) equipped with an automatic recording of intruded Hg volume was used to 
assess pore size ranging in 0.007–300 μm diameters (n = 2). The distribution of pore 
volumes was obtained from the derivative curve of the cumulative intruded volume, as a 
function of pore diameter, using the following equation (Washburn, 1921): 
𝑑 = 10 ∙ 4𝛾 cos
𝜃
𝑃
 
which states that the diameter d (μm) of the Hg-filled pores (i.e., open pores), considered 
with a cylindrical shape, is inversely proportional to the intrusion pressure P (kg/cm2), if the 
Hg surface tension γ and the contact angle θ between Hg and the material are constant. In 
our experimental conditions, γ = 0.48 N/m  and θ = 141°.  
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2.2.4. Cell isolation and expansion of MSC 
The human MSCs cells were obtained for bone narrow aspirates from patients undergoing 
hip surgery at the Orthopedic Division of “Azienda Ospedaliera Universitaria Pisana”. Bone 
marrow samples were collected after informed consent, treated anonymously and in 
conformity to the principles expressed by the Declaration of Helsinki. Briefly, the bone 
marrow aspirate was diluted 1:4 in sterile saline and layered on Ficoll as a density gradient 
inside sterile tubes. The mononuclear cell layer), selected via centrifugation at 400×g for 
15 min, was suspended in culture medium, containing low-glucose D-MEM, 2 mM L-
glutamine, 100 IU/mL penicillin, 100 mg/mL streptomycin, 5 µg/ml levofloxacin and 10% 
(v%) heat-inactivated FBS. The mononuclear cells were counted using a Burker chamber 
and plated at a density of 200,000 cells/cm2 in tissue-culture polystyrene flasks. After 24 
hours, the MSCs were purified from other non-adherent mononuclear cells via washing 
with sterile saline. When the cultures reached about 80% confluence, the MSCs were 
detached by using 0.25% trypsin and replated at a density of 1000 cells/cm2 to allow their 
expansion. Cell cultures were carried out in incubator under standard conditions, namely 
37°C, 95% relative humidity, and 5% CO2/95% air environment.  The MSCs were seeded 
at passage 2 on the PVA/G scaffolds at a density of 200.000 cells/scaffold (1st experiment) 
and 250.000 cells/scaffold (2nd experiment) for selecting the best scaffold composition. 
 
2.2.5. MSCs characterization 
Once isolated, the MSCs were committed towards multi lineage differentiation in order to 
assess their multipotency, and thus confirming their constitutive stemness. The MSCs 
were committed towards three well-known mesodermal lineages: osteogenic, adipogenic 
and chondrogenic.For inducing adipodifferetiation 50.000 cells/ml were risuspended in NH 
Adipodiff medium and 1,5 ml of cellular suspension was seeded which corresponds to 
75.000 cells. the medium was changed every three days and the culture was performed 2-
3 weeks, until the formation of fatty droplets inside the cytoplasm was visible under the 
inverted light microscope. After, the cells were fixed with 1 %Formalin and stored for 
further analysis. For chondrogenic differentiation, 250.000 MSCs were resuspended in 1 
ml of NH Chondrodiff medium and centrifuged at 150×g for 5 minutes (600 rpm) to obtain 
a cell pellet which was cultured for 3 weeks upon medium change every three days. At the 
endpoint, the pellet was fixed using 1%Formalin. To assess osteodifferentiation, the MSCs 
were cultured using Osteodiff Medium. The MSCs were plated at a density of of  60.000 
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cells/2 ml, and the medium was replaced evrey three days for three weeks. The cells were 
fixed using 1%Formalin.As functionality assays for these three protocols, Osmium 
tetroxide staining, which stains fatty droplets in black, Alcian Blue staining at pH 1, which 
stains sulphated glycosaminoglycans in cyan, and von Kossa staining, which stains 
calcium salts in black , and were performed for adipogenesis, chondrogenesis and 
osteogenesis (Figure 3.5) 
Adipogenic differentiation was detected by incubating the cells with 1% w/v OsO4 PBS 0.1 
M pH 7.2 (for 1 h. This staining shows the presence of lipid droplets in the cytoplasm, 
typical of the adipocytes. The other cytochemical staining were performed as described o 
later in paragraph. 
 
2.2.6. Isolation and culture of MPC 
Bone marrow aspirates (5-10 ml) were obtained under local anesthesia from  orthopedic 
patients, undergoing routine total hip replacement surgery, after written consent. Bone 
marrow mononuclear cells (BMMNCs) were collected by density gradient centrifugation on 
Ficoll-Paque Plus, washed twice in sterile saline and plated in DMEM-LG supplemented 
with 10% of pooled human AB sera (AB human sera, male only, from Lonza ( Euroclone) 
at 0.8x106/cm2 on hydrophobic untreated 25 cm2 flasks (Sarsted). After 8-10 days the cells 
were detached with TrypLE Select (Life Technology) for 15-20 min at 37°C, 5% CO2 and 
counted. 
 
2.2.7. Endothelial differentiation of MPC 
To perform endothelial differentiation, MPC were plated at 10,000 cells/cm2 in EndoCult on 
25 cm2 tissue culture flasks coated with  human fibronectin at 5 μg/cm2 for 30 minutes at 
room temperature, then rinsed, and cultured for 2-3 weeks. Pre-endothelial cells were then 
detached with trypsin digestion and counted. At the same time, MPCs were also cultured  
for 2-3 weeks in EGM-2 medium on human fibronectin coated 25 cm2 flasks (10.000 
cells/cm2). Such cells, supposed to be pre-endothelial cells, were detached with trypsin 
digestion and counted. Pre-endothelial cells obtained from both EGM-2 and Endocult 
cultures, were seeded on scaffolds (500.000 cells/scaffold) which were subsequently 
coated with Matrigel (100 µl/scaffold) (Becton Dickinson), incubated at 37 °C, 5% CO2 for 
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1 hour, then covered with EGM-2 medium containing 50 ng/ml of VEGF and incubated 
again for 20 hours at 37°C, 5%CO2. 
Parallel cultures were performed on 8-well chamber slides (1,5 cm2/well) previously coated 
both with human fibronectin (100 µl/well) and with  Matrigel (100 µl/well), the latter to 
obtain terminal differentiation. Slides with MPC and MSC were performed as controls. 
Slides from pre- and terminal differentiation were fixed for 10 min in Buffer formalin 1 % at 
4°C and constructs (scaffolds MPC/Endothelial cells) were fixed in Neutral Buffer formalin 
4 % overnight for immunocytochemistry analysis. 
 
2.2.8. Culture differentiation of HUVEC 
HUVEC were purchased from Promocell© Laboratories. Briefly, cryopreserved cells were 
thawed and seeded in a 25 cm2 flask previously filled with EGM-2 medium and incubated 
for 30 minutes at 37°C, 5%CO2. After 24 hours the medium was changed medium and 
when confluence (70-90%) was reached, cells were trypsinized and replated for further 
expansion.      
 
2.2.9. Culture and differentiation of HUVEC on PVA/G scaffolds 
HUVEC were loaded on different PVA/G (100/0, 90/10,80/20, 70/30 and 50/50) scaffolds 
(200.000 cells/scaffold). First, scaffolds were sterilized in absolute alcohol for minimum 24 
hours, rinsed with 2% glycine solution for 1 hour, following three washes of 15 minutes 
with PBS. Then, HUVEC were detached with 1 ml of Trypsin 0.25 % (v/v) for 5 minutes in 
CO2 incubator and centrifuged for 5 minutes. The cell pellet was resuspended at 200.000 
cells/20 µl in gelatin solution 2% and 20 µl of cell suspension were loaded on each 
scaffold, which were let previously dry in a 6 well plate under the biohood. The plate was 
then incubated for 1 hour at 37°C, 5% CO2 and, subsequently, 1 ml of EGM-2 medium was 
added. 
 
2.2.10. Culture and differentiation of MSC on PVA/G scaffold 
MSC (250.000 cells) were loaded on different types of PVA/G scaffolds (100/0, 
90/10,80/20, 70/30 and 50/50). First, scaffolds were sterilized in absolute alcohol for 
minimum 24 hours, rinsed with glycine 2% for 1 hour, following three washes of 15 
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minutes with PBS. Then, MSC were detached with 1 ml of Trypsin 0.25 % (v/v) for 5 
minutes in CO2 incubator and centrifuged for 5 minutes. The cell pellet was resuspended 
at 250.000 cells/20 µl in 2% gelatin solution and 20 µl of the cell suspension was loaded 
on each scaffold, previously dried in 6 well plate. The plate was then incubated for 1 hour 
at 37°C, 5% CO2 and, subsequently, 1 ml of DMEM-LG supplemented with 2 mM 
Glutamine, 10 % FBS, 100x penicillin/streptomycin, 5 mg/ml Levofloxacin and 100x 
fluconazole. The next day The medium was changed and differentiation factors such as 
dexamethasone (0.1 µM), β-glycerophosphate (10 mM), and ascorbic acid (50 µg/ml) were 
added twice a week to the medium for 3 weeks.  
 
2.2.11. Co-culture of osteodifferentiated MSCs and HUVECs on the selected PVA/G 
scaffold 
The co-culture was performed on the selected scaffold, which resulted best suitable for 
both HUVEC and MSC, On this scaffold, the osteodifferentiation process was performed 
for 21 days before HUVEC seeding, in order to have a mature bone ECM. The 
MSC/scaffold constructs were let rest 1 day inside a culture medium constituted by 1/1 
osteogenic medium/EGM-2 prior to HUVEC seeding. HUVEC were seeded at a density of 
200.000 cells per scaffold, and differentiated for 24 hours, according to the following 
conditions:  
1) On live osteoblast/scaffold constructs, HUVEC were seeded (i) with Matrigel® (100 µl of 
Matrigel® previously warmed at 37°C for 1 hour); and (ii) without Matrigel®.   
2) On lysed osteoblast/scaffold constructs, HUVEC were seeded i) with Matrigel® (100 µl 
of Matrigel® previously warmed at 37°C for 1 hour); and (ii) without Matrigel®.   
The first condition served to assess the necessity for Matrigel®  for HUVEC differentiation 
in presence of bone ECM, while the second condition served to assess the influence of 
osteoblast-endothelial cell cross-talk for HUVEC differentiation. In this case, the HUVEC 
were seeded on a scaffold containing only a bone pre-generated ECM, without living 
osteoblasts. The cell lysis was performed adding to the constructs 2 ml of sterile distilled 
water inside sterile tubes, then freezing (at -81°C for 1 day) and thawing (at 37°C for 30 
min) under sonication. The pre-generated ECM scaffolds were rinsed with saline and dried 
under the biohood before seeding.  
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After seeding HUVEC, 100 µl of EGM-2 medium were added to the constructs and pre-
generated ECM scaffolds, and placed in incubator (37°C, 5% CO2) for 30 minutes.  In the 
samples treated without Matrigel® , 500 µl of EGM-2 medium was added. After 18 hours of 
differentiation, the samples were fixed  with 4% neutral buffered formalin overnight.   
 
2.2.12. Co-Culture of MSC and pre-endothelial cells derived from MPC  
MSC and pre endothelial cells were obtained from bone marrow samples, the latter via 
MPC, as described earlier in paragraphs 2.2.6 and 2.2.7. On the selected PVA/G scaffold, 
MSC were osteodifferentiated for 14 days using OsteoDiff Medium (which accelerates the 
differentiation with respect to regular osteogenic medium) and live osteoblast constructs 
were used for endothelial cell seeding and differentiation. Specifically, the constructs were 
improved adding more MSCs (500.000 cells) and endothelial cells (400.000 cells) with 
respect to 2.2.11 paragraph, namely Co-culture of osteodifferentiated MSC and HUVEC 
on the selected PVA/G scaffold.The experiment as described in paragraph 2.2.11 was 
repeated using:  
1) HUVEC with (i) undiluted Matrigel® and, (ii) 1:1 diluted Matrigel®, to optimize the 
previous results; 
2) MPC-derived pre-endothelial cells culture with EGM-2 and Endocult media, to 
assess the possibility to assemble a completely autologous pre-vascularized bone 
substitute. 
 
Treatments Cellular density   
EGM-2/Endothelial 25.000 
Endo/MPC  250.000 
HUVEC 25.000 
MPC/EGM-2 25.000 
Table 1. Cellular density use for each treatment 
 
The chambers slide after culture were fixed for 10 minutes in 4% phosphate-buffered 
formalin for immunohistochemically analysis. 
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2.2.13. ALAMAR BLUE™ assay. 
The metabolic activity of the cells grown on the scaffolds was monitored along the culture 
time using the alamarBlue® assay. This bioassay incorporates a REDOX indicator 
resulting in color change of the culture medium according to cell metabolism. Moreover, it 
can be performed multiple times on the same samples on account of its negligible toxicity. 
The data were acquired according to the manufacturer’s instructions and expressed as 
percentage of reduced alamarBlue® (%ABred). Briefly, samples (n = 2) and negative 
controls (n = 2), namely, media plus dye without cells, by using equation #1 from the 
manufacturer, were incubated for 3 h at 37°C with the alamarBlue® dye diluted in 3 ml of 
culture medium for each scaffold, according to the manufacturer’s recommendations. This 
method for calculation against negative controls is useful to assess %ABred increase of the 
same samples along a timeline. The total quantity of dye solution per well was chosen in 
theoretical excess, in order to accomplish any metabolic activity increases all the samples 
in long term cultures. Viability tests were performed every week after seeding for MSC and 
prior and post differentiation for HUVEC. At each time-point, 100 μL of supernatant from 
sample or control was loaded into 96-well plates; then, excess supernatant was removed 
from the cultures and replaced with fresh CM. The absorbance () of supernatants was 
measured with a spectrophotometer (Victor 3; PerkinElmer, Waltham, MA, USA) under a 
double wavelength reading (570 nm and 600 nm). Finally, %ABred was calculated by 
correlating the absorbance values and the molar extinction coefficients of the dye at the 
selected wavelengths, following the protocol provided by the manufacturer. The equation 
applied (Eq. 1) is shown below, in which:  = absorbance, s = sample, and c = negative 
control: 
%𝐴𝐵𝑟𝑒𝑑 = 100 ∙
(117,216 ∙ 𝑠(570 𝑛𝑚) −  80,586 ∙ 𝑠(600 𝑛𝑚))
(155,677 ∙ 𝑐(600 𝑛𝑚) −  14,652 ∙ 𝑐(570 𝑛𝑚))
 
The data were processed using InfoStat© Sotfware for statistical analysis  
 
2.2.14. Fixation, Paraffin Embedding and sectioning 
Chambers slides seeded with HUVEC and MPC cells and 6-well culture plates seeded 
with MSC differentiated towards osteogenic and adipogenic lineages were fixed in 1% v/v/ 
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neutral buffered formalin diluted in PBS 1X for 10 min at 4°C and, after formalin removal, 
they were air dried and stored at 4°C.  
Seeded PVA scaffolds and chondrogenic pellet were fixed in neutral buffered formalin 4% 
w/v overnight at 4°C, washed with PBS 1X 4 times for 15 minutes and stored in 70% 
Ethanol. Then, they were dehydrated with a graded series of ethanol: 80% ethanol for 30 
min, 95% ethanol for 45 minutes, absolute ethanol 3 h (three changes of 1 h each one), 
then they were clarified in Xylene twice or 45 min. All the steps were performed in a bath 
at 40°C. Subsequently, specimens were rinsed in liquid paraffin in a vacuum oven at 60°C 
for 2h, placed in wax embedding box and air dried.  Paraffin blocks were sectioned with a 
standard microtome to obtain 6-m-tick sections that were mounted on glass slides and 
stored in a bath at 37°C for 1 day, in order to permit a correct adhesion of the paraffin 
sections on the slides. 
 
2.2.15. Cytochemistry 
von Kossa  
This staining was performed on MSC differentiated towards osteogenic lineage in order to 
reveal, in black, deposits of calcium phosphate, typical of bone mineralized matrix.   
After two washing in distilled water,  the cells were incubated with 1% w/v silver nitrate 
exposed to light for 15 min, 0,5% w/v Pyrogallol for 2 minutes and 5% w/v sodium 
thiosulphate for 2 min. All the solutions were maked in distilled water. After each passage 
washings in distilled water were performed. The counterstaining was performed incubating 
cells with 0,1% w/v nuclear fast red diluted in a distilled water solution containing 5% w/v 
aluminium sulphate, for 5 min and washing in tap water for 5 min in order to reveal the 
reaction. 
Osmium tetroxide  
This staining was performed on MSC differentiated towards adipogenic lineage in order to 
reveal, in black, the presence of lipidic drop in the cytoplasm, typical of the adipocytes. 
The cells were incubated with 1% v/v osmium tetroxide diluted in PBS 1X for 1 h, then 
washed twice in PBS1X for 10 min.   
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2.2.16. Histochemistry 
Before each staining, sections of both seeded PVA and chondrogenic pellet were 
deparaffinized rinsing them in xylene twice for 7 min, then they were rehydrated by 
absolute ethanol three times for 7 min and washing them in distilled water for 5 min; after 
each staining, the sections were dehydrated by three washes in absolute ethanol and 
clarified by three washes in xylene (5 min for each step), then they were mounted with a 
coverslip using a mountant medium diluted in xylene (DPX mountant). 
All stainings were performed on seeded PVA; on sections of chondrogenic pellet, only 
Alcian Blue pH1 was performed. 
Hematoxylin-Eosin (H&E) 
H&E staining was performed in order to reveal cell general morphology and scaffold 
colonization. 
Sections were incubated with Mayer’s hematoxylin for 5 min and washed with tap water to 
reveal the staining; then, they were incubated with 0.003% w/v eosin in distilled water for 1 
min and washed in distilled water.  
von Kossa  
von Kossa staining was performed as previously described. 
Alcian Blue pH1 and pH2.5 
This staining showed, in cyan, the presence of sulphated acid (pH1) and generic acid 
(pH2.5) glycosaminoglycans in the samples. 
Sections were incubated by alcian blue solutions for 30 min, then with revealing solutions 
for 10 min, according to manufacturer’s instructions. After washing in distilled water, 
specimens were counterstained with Nuclear fast red as previously described for von 
Kossa staining. 
Periodic acid Schiff (PAS) reaction 
PAS staining revealed, in magenta, the presence of glycoproteins in the samples.   
Sections were incubated with 1% w/v periodic acid solution in distilled water for 10 min and 
air dried prior to incubate them with  Schiff reagent 15 min. The reaction was revealed by 
washing in tap water for 10 min. Counterstaining was performed incubating the sections 
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with Mayer’s hematoxylin for 5 min and revealing the reaction washing them in tap water 5 
min.  
 
2.2.17. Immunocytochemistry 
After two washing in distilled water, chamber slide seeded with MPC and HUVEC were 
permeabilized by 0.2% v/v Triton X-100 in PBS 1X for 10 min and washed twice in PBS 1X 
for 5 min. Quencing of endogenous peroxidases was performed by incubation with 0.6% 
H2O2 in methanol for 15 min in the dark. After washing in PBS 1X for 10 min, samples 
were incubated with 20% v/v Goat serum diluted in  PBS 1X for 20 min at 37°C in order to 
block aspecific binding sites of the secondary antibodies. After washing in PBS 1X for 5 
min, sections were incubated with primary antibodies diluted in 0.1% w/v BSA/PBS 1X 
solution in moisted chamber at 4°C overnight: anti-PECAM 1:50, anti-VEGF-R2 1:50, anti 
p-VEGF-R2 1:50, anti VEGF 1:200.Negative controls were performed incubating sections 
with 0.1% w/v BSA/PBS 1X solution only. 
Next day, specimens were incubated with goat anti-rabbit or goat anti-mouse biotinylated 
secondary antibodies diluted 1:200 in 1.5% v/v goat serum-PBS 1X solution for 60 min, 
then with streptavidin solution for 30 min, prepared according manufacturer’s instructions. 
In order to reveal the reaction, the sections were incubated in the substrate-chromogen 
solution (0.5 mg/mL 3,3 min-diaminobenzidine tetrahydrochloride containing 0.02% H2O2) 
for 5 min in the dark, counterstained with Mayer’s hematoxylin for 1 min and washed in tap 
water for 1 min. Finally, the sections were mounted with an aqueous mountant medium. In 
the second part of reaction, after each passage, washings in 0.01% v/v Triton/ PBS 1X 
and  PBS 1X solutions were performed. 
 
2.2.18. Immunohistochemistry (IHC) 
Sections of seeded PVA were deparaffinized rinsing them in xylene twice for 7 min, then 
they were rehydrated by absolute ethanol three times for 7 min and washing them in 
distilled water for 5 min. The IHC protocol steps are the same reported in the previous 
part. The employed primary antibodies were: anti-ALP 1:100, anti-OPN 1:2000, anti-
Collagen I 1:1000, anti-Osteocalcin 1:400, anti-TGFβ-1 1: 500, anti-PECAM 1:100, anti-
VEGF-R2 1:50, anti p-VEGF-R2 1:50, anti VEGF 1:200. After the counterstaining the 
sections were dehydrated by three washes in absolute ethanol and clarified by three 
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washes in xylene (5 min for each step), then they were mounted with a coverslip using a 
mountant medium diluted in xylene. 
 
All the histological analysis were observed with a Nikon Eclipse Ci microscope (Nikon 
Instruments, Amsterdam, The Netherlands) and the images were acquired by a digital 
camera equipped on the microscope.  
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Chapter 3 
 
3.RESULTS 
 
3.1. SCAFFOLD CHARACTERIZATION  
The five composition types of PVA/G scaffolds were characterized using SEM to assess 
their morphology and with MIP to assess their pore size distribution. SEM images of all 
scaffolds showed highly porous structures, with round interconnected pores (Figure 3.1). 
In addition, these diverse PVA/G compositions resulted to display decreasing surface 
roughness, having 100/0 the roughest and the 50/50 the smoothest surfaces.  
 
 
            100/0         90/10       80/20  70/30         50/50 
 
 
 
 
 
 
 
 
 
 
 
These PVA/G scaffolds also showed a diverse pore size distribution (Figures 3.2 and 3.3). 
Specifically, the higher G content scaffolds retained the higher relative volume % of pores 
belonging to higher diameter classes, such as 300-100 μm and 100-30 μm, while the lower 
G content scaffolds had higher relative volume % of pores belonging to lower diameter 
classes, such as 30-10 μm and 10-3 μm (and also 1-0.3 μm).   
Figure 3.6. SEM morphology of PVA/G scaffolds at various compositions. The micrographs showed 
scaffold pores (upper line), and pore interconnectivity and surface roughness (lower line). The 
PVA/G 100/0 scaffold showedhe highest while 50/50 the smothest surface roughness.   
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Figure 3.2. MIP analysis of PVA/G scaffolds with compositions 100/0, 90/10, 70/30 and 50/50 
showing pore size distribution according to pre-defined pore size classes 
 
 
 
Figure 3.3. MIP analysis of PVA/G scaffolds with compositions 80/20 showing pore size 
distribution according to pre-defined pore size classes 
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3.2. MSC CHARACTERIZATION  
Morphology of MSCs in culture highlighted big spindle-shaped adherent cells arranged into 
colonies 
                  
 
 
 
 
 
 
 
MSC were characterized through their capability of differentiating towards the three well-
known mesodermal lineages (osteogenic, adipogenic and chondrogenic). The results of 
the differentiation assays are shown in Figure 3.5. 
 
Figure 3.5. Citochemistry on MSC multilineage differentiation assays. Black mineralization 
granules, in black, in osteodifferentiated MSC (A); fatty vacuoles, in black, in MSC differentiated 
towards adipogenic lineage (B); sulphated glycosaminoglycans, in cyan, in MSC differentiated 
towards chondrogenic lineage (C). 
 
              
Figure 3.4. Inverted microscope images showing MSCs with spindle-shaped 
morphology, assembled into colonies, adherent cells on flasks. 
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Osteogenic differentiation was assessed using von Kossa staining that showed mineral 
matrix deposition in black; adipogenic differentiation was highlighted by presence of fatty 
vacuoles, stained in black by osmium tetroxide; chondrogenic differentiation was displayed 
by the presence of sulphated glycosaminoglycans, which are stained in cyan by Alcian 
Blue staining at pH 1 
 
3.3. ENDOTHELIAL CELL CHARACTERIZATION. 
 
HUVECs showed round morphology during expansion. Upon culture in EGM-2 medium 
HUVECs displayed the formation of tubes or pre-vascularized structures on the chambers 
slides (Figure 3.6). 
 
Figure 3.6 Tube formation using EGM-2 medium. A) HUVEC in total confluency on flask ;B-D) 
Formation of endothelial tubes. Magnification x100. 
 
 
47 
 
3.4. ENDOTHELIAL DIFFERENTIATION OF MPC AND HUVEC  
Immunocytochemical analysis for endothelial markers was performed on MPC and 
HUVEC differentiated towards endothelial lineage in different conditions. (Figure 3.7 and 
3.8) 
Undifferentiated MPC: the cells showed strong positivity (++/++++; +++) for VEGF, VEGF-
R2  and PECAM. No tube formation was observed. 
MPC cultured in EGM2: good positivity (++) was observed for VEGF and VEGF-R2; many 
cells showed weak positivity (-/+; +) for PECAM, but some spindle shaped cells showed 
strong positivity. Negative cells were also observed. P-VEGF-R2 was not expressed. No 
tube formation was present. 
MPC cultured in EGM2 on fibronectin: all endothelial markers were weakly expressed. 
Negative cells were also observed. No tube formation was observed. 
MPC cultured in EGM2 on matrigel: all endothelial marker expression was negative. Tube 
formation was observed. 
MPC cultured in Endocult on fibronectin: all endothelial markers were not expressed. No 
tube formation was observed. 
MPC cultured in Endocult on matrigel: only few cells showed good expression of p-VEGF-
R2. PECAM expression was negative. Tube formation was observed. 
HUVEC cultured on fibronectin: weak expression of PECAM and p-VEGF-R2 was 
observed. No tube formation was revealed. 
HUVEC cultured on matrigel: PECAM and p-VEGF-R2 expression was negative. Tube 
formation was observed. 
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Figure 3.7. Immunohistochemistry on MPC differentiated on endothelial cells First column: VEGF; 
second column: VEFG-R2; third column: p-VEGF-R2; fourth column: PECAM. First line: MPC 
undifferentiated; second line: MPC cultured in EGM-2; third line: MPC cultured in EGM-2 with 
fibronectin; fourth line: MPC cultured in EGM-2 with Matrigel. Magnification 200x 
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Figure 3.8. Immunohistochemistry on endothelial differentiation of MPC and HUVEC. First column: 
p-VEGF-R2; second column: PECAM; First line: MPC cultured in endocult on fibronectin; second 
line: MPC cultured in endocult on matrigel; third line: HUVEC cultured on fibronectin; fourth line: 
HUVEC cultured on matrigel. Magnification 200x 
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3.5 CHARACTERIZATION OF HUVECS CULTURED ON PVA/G SCAFFOLDS.  
HUVECs were seeded and differentiated on the different PVA/G scaffold types to evaluate 
the best suitable PVA/G composition for this cell type. In the first experiment 150.000 
cells/scaffold were seeded. This number was probably low, however some cells were 
observed on each type of scaffolds and also tube formation could be sometimes imaged 
(Figure 3.9). In PVA/G 50/50, the HUVECs showed a round shape, while in 100/0 they 
were rarely imaged. The highest presence of cells with elongated morphology was 
detected in the PVA/G 80/20 scaffold. 
 
Figure 3.9.  HUVECs cultured  on  PVA/G scalffolds. First column: Hematoxylin-Eosin;  second 
column: SEM images. First column  magnification x200; second column: magnification x1000-3000 
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3.6. CHARACTERIZATION OF MSCS OSTEODIFFERENTIATED ON PVA/G 
SCAFFOLDS  
MSC were differentiated towards the osteogenic lineage on the PVA/G scaffolds with 
different compositions to assess the best suitable scaffold for bone. At the endpoint, cell 
morphology and mineral matrix formation were investigated using histology and SEM. The 
osteoinduced MSCs were able to colonize all the scaffolds and produce mineral ECM, as 
shown by SEM and von Kossa staining (Figure 3.10). On PVA/G 100/0 scaffold a reduced 
number of osteodifferentiated MSCs were observed. Von Kossa staining showed 
mineralization in the scaffold wall, SEM analysis confirmed scarcity of cells. On PVA/G 
90/10 scaffold suffering cells were observed, granules of ECM were present in the scaffold 
and SEM analysis confirmed the formation of mineral matrix deposition. On PVA/G 90/10 
80/20 scaffold, a good presence of cells in the pores was observed, having mainly spindle-
shaped morphology while round shaped cells were scarcely detected, many pores were 
colonized by cells and the formation of mineralization granules was corroborated with SEM 
analysis and von Kossa staining. The PVA/G 70/30 scaffold showed cells in good number. 
The MSCs did not colonize all the scaffold and where grouped into clusters; in some cases 
they appeared scattered with roundish morphology. The von Kossa staining highlighted 
the formation of mineralization granules. In the PVA/G 50/50 scaffold the cells had round 
morphology and represented in limited number. However, the presence of mineral ECM 
was detected. 
After analyzing the diverse characteristics, the distribution and localization of the cells on 
all the scaffolds, the PVA/G80/20 and 70/30 scaffolds appeared the most promising for 
reproducing a bone substitute in vitro.  
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Figure 3.10.  MSCs osteodifferentiated on PVA/G scaffolds: first column: Hematoxylin-Eosin; 
second column: SEM images; third column: von Kossa. First line: PVA/G 100/0; second line: 
PVA/G 90/10; third line: PVA/G 80/20; fourth line: PVA/G 70/30; fifth line: PVA/G 50/50. First and 
second columns magnification x200; third column: magnification x500-1000. 
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3.6.1 Alamar Blue™ Assay Results. 
Results are evaluated by plotting the fluorescent (or absorbance) signal versus compound 
concentration and calculous percent reduction of metabolic activity. The amount of 
fluorescence produced is proportional to the number of living cells.( Fig 3.9 and 3.10) 
 
 
Figure 3.11 Test of vitality Percent of metabolic reduction on PVA/G scaffold 100/0, 90/10, 80/20, 
70/30 and 50/50. Average Value of six readings in one scaffold. 
 
 
Figure 3.12. Test of vitality Percent of metabolic reduction on PVA/G scaffold 80/20 and 70/30. 
Average Value of six readings in one scaffold. 
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3.7. CHARACTERIZATION OF CELLULARIZED AND DECELLULARIZED PVA/HUVEC 
CONSTRUCTS. 
 
3.7.1. Histochemistry  
Co-culture on scaffolds of MSCs osteodifferentiated in osteoblast with HUVECs was 
performed and HUVEC cells was seeded 200.000 cells each scaffold in co-culture media 
of DMEM: ECGM/ supplement mix. Decellurarization and cellularization scaffolds were 
performed presenting the follow histological characteristics (Figure 3.13 and 3.14). 
General morphology: H&E staining showed that, in PVA/HUVEC decellularized constructs 
without and with matrigel, very scarce cell colonization was evident. In PVA/HUVEC 
cellularized construct without matrigel some cell in the scaffold pores were observed and 
in PVA/HUVEC cellularized construct with matrigel small spindle-shaped cells adherent to 
the scaffold pore surfaces were highlighted. 
 
Glycoprotein expression: PAS reaction performed on PVA/HUVEC decellularized 
constructs without and with matrigel showed that only few cells were positive (+) for this 
staining, highlighting scarce presence of glycorpoteins. In PVA/HUVEC cellularized 
construct without matrigel some cells showed good positivity (++), many others appeared 
negative. In PVA/HUVEC cellularized construct with matrigel the cells adherent to the 
scaffold pores were negative; the positivity (+) was limited to some cells present in the 
pore scaffold. 
 
GAG expression: Alcian Blue staining at pH1 revealed that sulphated acid GAGs were not 
expressed in all the constructs. Alcian Blue staining at pH2.5 showed that in PVA/HUVEC 
decellularized constructs without and with matrigel, generic acid GAGs were not 
expressed. In PVA/HUVEC cellularized construct without matrigel, weak positivity was 
evidentiated. In PVA/HUVEC cellularized construct with matrigel the cells adherent to the 
scaffold pores and some cells present in the pores showed good positivity; some negative 
cells were observed. 
 
Mineralized matrix: von Kossa staining revealed that mineralized matrix granules were 
deposited on the scaffold surfaces in all the constructs, mainly in the PVA/HUVEC 
cellularized constructs. 
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Figure 3.13. Histochemistry on PVA/G scaffolds 80/20 with osteodifferentiated MSC and with 
HUVEC. First column: Hematoxylin-Eosin; second column: Alcian Blue pH 1.0;  third column: 
Alcian Blue pH 2.5. First line: PVA/HUVEC decellularized construct without Matrigel; second line: 
PVA/HUVEC decellularized construct with Matrigel; third line: PVA/HUVEC cellularized construct 
without Matrigel; fourth line: PVA/HUVEC cellularized construct with Matrigel. Red arrows = cells. 
Magnification x200. 
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Figure 3.14. Histochemistry on PVA/G scaffolds 80/20 with osteodifferentiated MSC and with 
HUVEC. First column: PAS reaction; second column: von Kossa. First line: PVA/HUVEC 
decellularized construct without Matrigel; second line: PVA/HUVEC decellularized construct with 
Matrigel; third line: PVA/HUVEC cellularized construct without Matrigel; fourth line: PVA/HUVEC 
cellularized construct with Matrigel. Red arrows = cells. Magnification x200 
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3.7.2. Immunohistochemistry 
 
Many osteogenic and endothelial markers were tested on PVA constructs, as reported on 
the table 1, in order to evaluate the most suitable for construct characterization. Due to 
very scarce cell presence in some constructs, not all the markers were detectable. 
Between osteogenic markers detected, it was observed weak ALP expression in 
PVA/HUVEC cellularized constructs and weak positivity for TGFβ-1 in PVA/HUVEC 
decellularized construct without matrigel. 
Between endothelial markers detected, strong positivity for VEGF in PVA/HUVEC 
cellularized constructs and PVA/HUVEC decellularized construct without matrigel was 
observed. Moreover, VEGF-R2 was weakly expressed in PVA/HUVEC cellularized 
construct without matrigel. 
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Figure 3.15. Immunohistochemistry for endothelial and osteogenic markers on the constructs. First 
column: VEGF; second column: VEGF-R2; third column: ALP; fourth column: TGFβ-1. First line: 
PVA/HUVEC decellularized construct without Matrigel; second line: PVA/HUVEC decellularized 
construct with Matrigel; third line: PVA/HUVEC cellularized construct without Matrigel; fourth line: 
PVA/HUVEC cellularized construct with Matrigel. Red arrows = cells. Magnification x200 
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Constructs PVA/HUVEC 
Decellularized 
w/o Matrigel 
PVA/HUVEC    
Decellularized  
w Matrigel 
PVA/HUVEC 
Cellularized 
w/o Matrigel 
PVA/HUVEC 
Cellularized    
w Matrigel Osteogenic 
markers 
ALP - ND + + 
OPN ND ND +++ +++ 
COLL I ND ND ND ND 
TGFβ-1 -/+ ND - - 
OCN -/+ ND ND ND 
Endothelial 
markers 
    
VEGF +++ ND +++ +++ 
VEGF-R2 ND ND -/+ - 
p-VEGF-R2 - ND - - 
PECAM +;-   ND - - 
 
Table 1. Osteogenic and endothelial markers tested on the constructs by IHC. ND = not 
detectable; - = negativity. -/+; + = weak positivity. ++ = good positivity. +++ = strong positivity. 
 
 
3.8. CHARACTERIZATION OF PVA/HUVEC AND PVA/MPC CELLULARIZED 
CONSTRUCTS. 
 
3.8.1. Histochemistry 
 
General morphology: H&E staining showed a strong scaffold colonization in the PVA/ 
HUVEC constructs with diluted and not diluted matrigel. The cells having a spindle-shape 
morphology were located in the scaffold pores as well as were adherent to the pore walls. 
The cells having round morphology were located in the scaffold pores only. In PVA/MPC in 
EGM2, both isolated and clustered cells were observed having spindle-shape and round 
morphology. In PVA/MPC in Endocult strong scaffold colonization was observed: the cells, 
having different shape, colonized scaffold pores and cell strips were detected to the 
scaffold periphery. 
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Glycoprotein expression: PAS reaction showed that in PVA/HUVEC construct with diluted 
matrigel glycoproteins were scarcely expressed. In PVA/HUVEC construct with not diluted 
matrigel, strongly PAS-positivity was observed in rounded cells, while spindle-shaped cells 
were weakly positive or negative. In PVA/MPC in EGM2 and in Endocult both strongly 
positive and negative cells were observed, but in the latter construct PAS-positive cells 
were more expressed than PAS negative cells. 
 
GAG expression: Alcian Blue staining at pH1 revealed no presence of sulphated acid 
GAGs in all constructs. Alcian Blue staining at pH2.5 showed that in PVA/HUVEC 
constructs with matrigel some cells expressed weak positivity for acid GAGs, others good 
positivity. In PVA/MPC constructs some cells showed good positivity, others were 
negative. 
 
Mineralized matrix: von Kossa staining showed that in all constructs some cells produced 
mineralization matrix granules that covered the cells and the scaffold also. 
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Figure 3.16 Histochemistry on PVA/G constructs with HUVEC and MPC. First column: 
Hematoxylin.Eosin; second column: Alcian Blue pH 1.0; third column: Alcian Blue pH 2.5.  First 
line: PVA/HUVEC construct with diluted matrigel:; second line: PVA/HUVEC construct with not 
diluted matrigel; third line: PVA/MPC construct in EGM-2: fourth line: PVA/MPC construct in 
Endocult. Magnification x200 
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Figure 3.17. Histochemistry on PVA/G constructs with HUVEC and MPC. First column: PAS 
reaction; second column: von Kossa. First line: PVA/HUVEC construct with diluted matrigel:; 
second line: PVA/HUVEC construct with not diluted matrigel; third line: PVA/MPC construct in 
EGM-2: fourth line: PVA/MPC construct in Endocult. Magnification x200 
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3.8.2. Immunohistochemistry 
 
Osteogenic markers 
In all the constructs, cells expressed good amount of ALP osteogenic marker were 
observed, but some cells negative were also present. Good immunopositivity for Collagen 
I was highlighted in PVA/HUVEC construct with diluted matrigel. In the other constructs, 
the expression of this marker was weak. Negative cells were also present. In PVA/HUVEC 
with diluted matrigel, no positive cells for TGFβ-1 were showed. In PVA/HUVEC with not 
diluted matrigel, different positivity was observed: some cells showed good expression for 
this marker, others weak expression and others were negative. PVA/MPC in EGM2 and 
PVA/MPC in Endocult showed good an strong expression, respectively, for TGFβ-1.(Figure 
3.18) 
 
Endothelial markers 
In PVA/HUVEC with diluted matrigel, only few cells expressed VEGF, but with good 
expression levels; in PVA/HUVEC with not diluted matrigel, both cells with scarce and 
strong positivity were observed; in PVA/MPC in EGM2, VEGF expression was weak, while 
was good in the cells of the PVA/MPC in Endocult construct. No presence of VEGF-R2 
was observed in PVA/HUVEC with not diluted matrigel and in PVA/MPC in EGM 2 
constructs, while this marker showed good expression in PVA/HUVEC with diluted 
matrigel and in PVA/MPC in Endocult constructs. Finally, PECAM was expressed only in 
few cells present in PVAHUVEC constructs, while in the others constructs was not 
expressed.(Figure 3.19). 
 
Constructs PVA/HUVEC    
w diluted 
Matrigel 
PVA/HUVEC    
w Matrigel 
PVA/MPC            
in EGM2 
PVA/MPC           
in Endocult Osteogenic 
markers 
ALP ++;- ++ ++;- ++;- 
COLL I ++;- +;- +;- -/+ 
TGFβ-1 - ++;-/+;- ++ +++;- 
Endothelial 
markers 
    
VEGF ++;- +++;+ -/+ ++ 
VEGF-R2 ++;-/+ - - ++ 
PECAM +- ; +;- - - 
Table 2. Osteogenic and endothelial markers tested on PVA/HUVEC and PVA/MPC constructs by IHC 
analysis. - = negativity. -/+; + = weak positivity. ++ = good positivity. +++ = strong positivity. 
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Figure 3.18 Immunohistochemistry for Osteogenic markers on PVA/G constructs with HUVEC and 
MPC. First column: ALP; second column: Col I; thid column: TGF-1. First line: PVA/HUVEC 
construct with diluted matrigel:; second line: PVA/HUVEC construct with not diluted matrigel; third 
line: PVA/MPC construct in EGM-2: fourth line: PVA/MPC construct in Endocult. Magnification 
x200 
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Figure 3.19. Immunohistochemistry for endothelial markers on PVA/HUVEC and PVA/MPC 
constructs. First column: VEGF; second column: VEGF-R2; thid column: PECAM. First line: 
PVA/HUVEC construct with diluted matrigel:; second line: PVA/HUVEC construct with not diluted 
matrigel; third line: PVA/MPC construct in EGM-2: fourth line: PVA/MPC construct in Endocult. 
Magnification x200 
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3.9 Statistical Analysis 
 
Statistical analysis was performed using variance analysis and Tukey test by InfoStat 
software (p,0.05) was considered to be significant. Results showed that exist difference 
significate between treatments.  The different treatment is 5 (50/50), all others have similar 
characteristics. (See supplements) 
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Chapter 4 
 
4.1 DISCUSSION 
 
The aim of this work was to develop an improved scaffold/cell construct for bone TE 
applications, constituted by PVA sponges seeded with osteodifferentiated MSCs and 
endothelial cells. The scaffolds behave as engineered matrices that provide structural 
support for 3D bone tissue formation (Rodriguez et al., 2011). The scaffolds can be 
designed with properties able to induce and direct cellular attachment, proliferation, 
migration, and differentiation, making them prominent tools in the bone TE field (Wojtowicz 
et al., 2010; Nyugen et al., 2012). In bone TE, the scaffolds serve as temporary structural 
supports for cell interactions and formation of bone ECM fundamental process for the bone 
formation. Furthermore, bone TE scaffolds have been used to deliver growth factors 
encapsulated within their structures and in some cases they resulted to facilitate the 
vascularization of the neo-tissue (Nyugen et.al, 2012). PVA is a synthetic polymer, water 
soluble and nonhazardous thus easy to handle, which can be used in several clinical 
applications (Peppas and Hansen, 1982; Preetti, 2015). PVA can be processed in several 
structures, and stabilized via physical and/or chemical crosslinking, thus becoming water 
insoluble. Porosity and pore interconnectivity are among the most important characteristics 
of a TE scaffold, because they greatly affect cell migration, ingrowth and nutrient diffusion 
for cell survival, can facilitate bone formation and the creation of a vascularization process. 
In general, scaffolds with large pore sizes can accommodate cells, cell aggregates and the 
secretion of ECM, while small pore sizes play a role in facilitating small molecule 
trafficking, such as nutrients, oxygen and metabolic waste. In this view, the production of 
scaffolds containing both macropores and micropores is highly recommended to promote 
an optimal microenvironment for cell growth and differentiation (Karageorgiou et al., 2005). 
It was demonstrated that optimum pore sizes should be larger than 100 μm for 
regeneration of vascularized bone tissue (Hulbert et al., 1970). In our study, we fabricated 
via emulsion and freeze-drying, and tested with MSCs and endothelial cells, PVA scaffolds 
containing different weight percentages of G (PVA/G 100/0, 90/10, 80/20, 70/30, 50/50), 
which ultimately resulted in different pore size distributions. Interestingly, the void volume 
was distributed into larger diameter pores in the scaffolds with higher G content. The best 
composition that we experimentally selected through independent cultures with MSCs and 
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HUVECs was the PVA/G 80/20. In this scaffold composition, 4.2% of the relative void 
volume was distributed into pores with 150-100 µm diameters, suitable for forming 
vascularized bone, 52.1% into 100-50 µm diameters, suitable for osteoblast housing, 41.7 
% into 50-10 µm diameters, suitable for endothelial cell colonization and  2% into pore 
diameters smaller than 10 µm, useful for molecule trafficking. It can be hypothesized that 
the combination of the polymeric blend composition (i.e., PVA/G 80/20), this specific pore 
size distribution, and the related surface roughness, altogether rendered this scaffold the 
most suitable for osteoblast and endothelial cell culture.    
 
We studied the capability of the PVA/G scaffolds with different compositions, to support 
MSC osteogenesis and new bone formation in vitro, to develop a model of bone TE 
scaffold on which endothelial cells could be cultured, so as to improve bone TE 
substitutes. The first investigations were performed culturing and differentiating HUVECs 
on the different PVA/G scaffolds. Two different cell densities were tested and the 
histological and SEM observations finally highlighted that PVA/G 80/20 and 70/30 were the 
best suitable scaffolds for HUVEC colonization. The second goal was to define the most 
suitable scaffold types for MSC osteodifferentiation. H&E staining showed several 
osteoblast-like cells colonizing all the scaffolds, but the best cellularized samples were the 
80/20 and 70/30 PVA/G compositions. Using von Kossa staining, mineralization evidence 
was also detected on all the scaffold types, possibly for the high interconnected porous 
scaffold characteristics that permitted an ideal environment for cell proliferation, 
vascularization and new bone formation to be generated (Nyugen et al, 2012). The 
morphological observations conducted with SEM showed that the cells attached and 
proliferated well on 80/20 and 70/30 PVA/G compositions, and these findings were also 
corroborated by the AlamarBlue® assay for the metabolic activity, which finally allowed the 
selection of PVA/G 80/20 as the best scaffold among all, to be used in further co-culture 
studies. These osteodifferentiated MSC/scaffold constructs were thus seeded with 
HUVECs. The first objective was to establish if bone ECM produced by the 
osteodifferentiated MSCs was sufficient to HUVEC differentiation or still needed Matrigel® 
as an endothelial differentiation supplement. Moreover, we tested if the endothelial 
differentiation occurred in presence of viable osteodifferentiated MSCs or without them, 
decellularizing the constructs prior to seeding them with HUVECs. The histological results 
showed that the best condition occurred when both viable osteodifferentiated MSC and 
Matrigel® were present on the constructs, giving rise to the formation of microcapillary-like 
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structures. These results are in line with other findings reported in literature (Santos et al., 
2010). These authors highlighted the complex interplay existing between angiogenesis 
and osteogenesis both in vivo and in vitro, that is fundamental for the vessel formation and 
new bone generation, and was confirmed by to gap junction formation between 
osteoblasts and endothelial cells (Santos et al, 2010). Also Wang et al. demonstrated the 
important relationship between osteoblasts and endothelial cells in co-culturing human 
osteoblast-like cells (HOBs) with HUVECs with an increase of ALP occurring only in co-
culture (Wang et al., 1997). In our HUVEC+MSC/scaffold constructs, an enhanced ALP 
positivity and improved endothelial cell morphology were detected in presence of live 
osteodifferentiated MSCs, thus confirming the fundamental role of osteoblast-endothelial 
cell cross-talk for an effective bone vascularization. Basing on these outcomes, the second 
objective was to optimize the co-cultured constructs and it was performed increasing the 
number of cells seeded on the scaffolds and the Matrigel® amount. The results showed 
that amorphous ECM molecules, osteogenic and endothelial markers were expressed 
more intensely than in previous constructs. In a similar fashion, enhanced pore 
colonization and endothelial cell differentiation were observed with respect to the previous 
experiments, in accordance with some authors who demonstrated that the ECM produced 
by bone-forming cells may promote the creation of microcapillary-like structures (Unger, et 
al., 2005; and Stanhl et al., 2003).  
 
Among the endothelial markers, VEGF is an important factor for the vessel formation, as 
well as a key player in physiological and pathological angiogenesis (Dvorak, 2000; 
Carmeliet, 2000; Ferrara et al.,1997,and 2003). VEGF can be functional to rise stem cell 
recruitment to damaged or diseased bone tissue and fracture healing (Beamer et al. 2010; 
Keramaris et al., 2008). In our constructs, VEGF was detected with good positivity in the 
cellularized and decellularized constructs without Matrigel®. PECAM-1 is another 
endothelial marker expressed by HUVECs, known to be crucial for vessel formation and 
maintenance. A weak PECAM positivity was observed on all our constructs. Networks of 
tubes or microcapillary in 2D HUVEC culture were observed in our experiments. The 
capacity of HUVECs to form these tubes is a relevant characteristic that may depend on 
the properties of the underlying ECM (Soucy, 2009). However, co-culture of endothelial 
cells with osteoblasts derived from osteoinduced MSCs can facilitate the tube formation in 
vitro on 3D scaffolds due to the production of cytokines and angiogenic growth factors 
(Deckers et al., 2008; Furumatsu et al., 2003). It is interesting to note that, among the 
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tested markers, ALP, VEGF and VEGF-R2 showed in many cases good expression, which 
is in line with the findings of Wang and coworkers, who reported an increase of these 
markers in co-cultures of osteoblasts and HUVECs (Wang et al.,1997). 
 
The ultimate objective of this study was to show the possibility to create a fully autologous 
prevascularized bone substitute using TE. This is theoretically possible, for example using 
the same stem cells to obtain osteoblasts and endothelial cells. Our strategy relied on the 
use of MPCs, a subset of immature stem cells present in the bone marrow, as they were 
proved to differentiate into MSCs and pre-endothelial cells (Petrini et al., 2009 ; Trombi et 
al.,2009 ) and to apply the most successful culture approach as obtained from the previous 
objective. The histological results showed very good expression of amorphous ECM 
molecules, osteogenic and endothelial markers, demonstrating that it could be possible, in 
perspective, to obtain a fully-autologous construct. 
 
 
4.2 CONCLUSIONS  
 
1) PVA/G 80/20 resulted the most suitable scaffold formulation for MSC and HUVEC 
culture, as revealed by viability assay and histo-morphological analyses.   
2) Co-culture method can represent a suitable strategy to improve TE constructs for bone 
regeneration studies.  
3) The presence of live osteodifferentiated MSCs and ECM molecules improved the 
endothelial differentiation in the 3D constructs. 
4)  Co-culture of MSCs and MPCs could be useful to obtain a fully autologous construct, 
useful, in perspective, for clinical applications.  
5) The expression of some osteogenic and endothelial markers in the constructs confirmed 
the results reported in literature, but at this stage of investigation, they were not as 
selective as expected to indisputably discriminate between the two cell types seeded on 
the scaffold. 
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4.5 SUPLEMENTARY  
Variance Analysis by InfoStat  
 
At Day 3 
 
Abbreviation. 
T1: Scaffold 100/0 
T2: Scaffold 90/10 
T3: Scaffold 80/20 
T4: Scaffold 70/30 
T5: Scaffold 50/50 
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Exist difference significate between treatments.  The different treatment is 5 (50/50), all 
others have similar characteristics. InfoStat Analysis say that averages with a common 
letter is not significantly different. 
 
At day 10 
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There are significant differences between treatments, treatment 5 has the highest average and is different 
from all other treatment 2 is the one with better results. 
At day 17 
 
At 21 Days 
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Before Embedding  
 
 
  
Day 1 
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Day 7 
 
 
 
 
Day 14 
 
Exists differences significantly between treatment  
 
